These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37245533)

  • 1. A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk - Study rationale and design.
    Davidy T; Yore I; Cukierman-Yaffe T; Ravona-Springer R; Livny A; Lesman-Segev OH; Azuri Y; Carmichael O; Kapogiannis D; Zetterberg H; Lin H; Sano M; Beeri MS
    Mech Ageing Dev; 2023 Jul; 213():111825. PubMed ID: 37245533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design.
    Davidy T; Yore I; Cukierman-Yaffe T; Ravona-Springer R; Livny A; Lesman-Segev OH; Azuri Y; Carmichael O; Kapogiannis D; Zetterberg H; Lin H; Sano M; Beeri MS
    Mech Ageing Dev; 2024 Apr; 218():111898. PubMed ID: 38159613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memory advancement by intranasal insulin in type 2 diabetes (MemAID) randomized controlled clinical trial: Design, methods and rationale.
    Galindo-Mendez B; Trevino JA; McGlinchey R; Fortier C; Lioutas V; Novak P; Mantzoros CS; Ngo L; Novak V
    Contemp Clin Trials; 2020 Feb; 89():105934. PubMed ID: 31923471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial.
    Novak V; Mantzoros CS; Novak P; McGlinchey R; Dai W; Lioutas V; Buss S; Fortier CB; Khan F; Aponte Becerra L; Ngo LH
    J Neurol; 2022 Sep; 269(9):4817-4835. PubMed ID: 35482079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Craft S; Raman R; Chow TW; Rafii MS; Sun CK; Rissman RA; Donohue MC; Brewer JB; Jenkins C; Harless K; Gessert D; Aisen PS
    JAMA Neurol; 2020 Sep; 77(9):1099-1109. PubMed ID: 32568367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
    Cukierman-Yaffe T; Gerstein HC; Colhoun HM; Diaz R; García-Pérez LE; Lakshmanan M; Bethel A; Xavier D; Probstfield J; Riddle MC; Rydén L; Atisso CM; Hall S; Rao-Melacini P; Basile J; Cushman WC; Franek E; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
    Lancet Neurol; 2020 Jul; 19(7):582-590. PubMed ID: 32562683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
    Craft S; Claxton A; Baker LD; Hanson AJ; Cholerton B; Trittschuh EH; Dahl D; Caulder E; Neth B; Montine TJ; Jung Y; Maldjian J; Whitlow C; Friedman S
    J Alzheimers Dis; 2017; 57(4):1325-1334. PubMed ID: 28372335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riesmeyer JS; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
    Lancet; 2019 Jul; 394(10193):121-130. PubMed ID: 31189511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
    Frias JP; Wynne AG; Matyjaszek-Matuszek B; Bartaskova D; Cox DA; Woodward B; Li YG; Tham LS; Milicevic Z
    Diabetes Obes Metab; 2019 Sep; 21(9):2048-2057. PubMed ID: 31050143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease.
    Rosenbloom M; Barclay TR; Kashyap B; Hage L; O'Keefe LR; Svitak A; Pyle M; Frey W; Hanson LR
    Drugs Aging; 2021 May; 38(5):407-415. PubMed ID: 33719017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J; Frias J; Jastreboff AM; Du Y; Lou J; Gurbuz S; Thomas MK; Hartman ML; Haupt A; Milicevic Z; Coskun T
    Lancet; 2023 Aug; 402(10401):529-544. PubMed ID: 37385280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
    Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
    Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease.
    Kellar D; Lockhart SN; Aisen P; Raman R; Rissman RA; Brewer J; Craft S
    J Prev Alzheimers Dis; 2021; 8(3):240-248. PubMed ID: 34101779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
    Gerstein HC; Hart R; Colhoun HM; Diaz R; Lakshmanan M; Botros FT; Probstfield J; Riddle MC; Rydén L; Atisso CM; Dyal L; Hall S; Avezum A; Basile J; Conget I; Cushman WC; Hancu N; Hanefeld M; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Muñoz EGC; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):106-114. PubMed ID: 31924562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): A randomized, double-blind, placebo-controlled, phase III trial.
    Wang W; Yan X; Cheng Z; Zhang Q; Wang R; Deng Y; Ma J; Zhu D
    Diabetes Obes Metab; 2023 Dec; 25(12):3690-3699. PubMed ID: 37732487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
    Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH
    Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
    Craft S; Baker LD; Montine TJ; Minoshima S; Watson GS; Claxton A; Arbuckle M; Callaghan M; Tsai E; Plymate SR; Green PS; Leverenz J; Cross D; Gerton B
    Arch Neurol; 2012 Jan; 69(1):29-38. PubMed ID: 21911655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study.
    Novak P; Pimentel Maldonado DA; Novak V
    PLoS One; 2019; 14(4):e0214364. PubMed ID: 31022213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and clinical implications of intranasal insulin on cognition in humans: A systematic review and meta-analysis.
    Wu S; Stogios N; Hahn M; Navagnanavel J; Emami Z; Chintoh A; Gerretsen P; Graff-Guerrero A; Rajji TK; Remington G; Agarwal SM
    PLoS One; 2023; 18(6):e0286887. PubMed ID: 37379265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.